Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Roth Mkm from $15.00 to $20.00. They now have a "buy" rating on the stock.
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $21.00. They now have a "buy" rating on the stock.